Connor, Clark & Lunn Investment Management Ltd.

Position in TBPH — Theravance Biopharma, Inc.

CIK 1596800 VANCOUVER, A1

Position in TBPH

as of Mar 31, 2026 · filed May 11, 2026 Compact

Position Value

$4,053,523

-$93,773 QoQ

Shares Held

249,755

+12.7% QoQ

Ownership

0.484%

of shares outstanding

% of Portfolio

0.01%

of 13F equity value

Holder Rank

—

not a current holder

Holding Since

Sep 2021

8 quarters on record

Voting authority Sole 100% Shared 0% None 0%

Healthcare · as of Mar 31, 2026

Connor, Clark & Lunn Investment Management Ltd. holds $669,981,685 across 100 Biotechnology names. TBPH ranks #41 (0.6% of the industry book) .

#	Ticker	Company	Shares	Value (USD)
1	VRTX	Vertex Pharmaceuticals Inc / Ma	251,711	$112,399,029
2	IONS	Ionis Pharmaceuticals Inc	874,089	$65,635,343
3	ARWR	Arrowhead Pharmaceuticals, Inc.	836,981	$52,478,708
4	MIRM	Mirum Pharmaceuticals, Inc.	479,476	$44,293,992
5	REGN	Regeneron Pharmaceuticals, Inc.	32,164	$24,851,192
6	AXSM	Axsome Therapeutics, Inc.	134,792	$22,782,543
7	SRPT	Sarepta Therapeutics, Inc.	1,019,951	$22,194,133
8	VKTX	Viking Therapeutics, Inc.	516,108	$16,794,154

8 filing rows on record

Report Date	Value (USD)	Shares	Change	Type	Discretion	Filed
2026-03-31	$4,053,523	249,755	+12.7%	Shares	Sole	2026-05-11
2025-12-31	$4,147,296	221,662	+26.8%	Shares	Sole	2026-02-10
2025-09-30	$2,552,620	174,837	+208.8%	Shares	Sole	2025-11-13
2025-06-30	$624,441	56,613	+253.3%	Shares	Sole	2025-08-07
2024-06-30	$135,875	16,023	-60.4%	Shares	Sole	2024-08-09
2022-03-31	$386,960	40,477	+22.5%	Shares	Sole	2022-05-12
2021-12-31	$365,025	33,034	-25.3%	Shares	Sole	2022-02-10
2021-09-30	$327,353	44,237	—	Shares	Sole	2021-11-12
No filing history on record for this holder in this stock.